Optimal Approaches to the Treatment of Castration-Resistant Prostate Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients' disease progresses despite castrate levels of testosterone.

Patients with all stages of CRPC have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer. This marker is used for early diagnosis and monitoring for disease recurrence.

The advances in treatment options in the past few years include the investigations of several novel targeted therapies, including androgen receptor (AR) targeting agents, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. Several of these drugs have either received approval from the FDA or have late stage development based on improvement of intermediate surrogate endpoints such as PSA levels or circulating tumor cell (CTC) counts in recent clinical trials. While the understanding of AR synthesis and regulation is well studied, no predictive markers have been adopted to guide development for the central pathway in early stage prostate cancer.

Upon completion of this activity, participants will be able to:

  • Evaluate efficacy and safety data of current and novel therapies for the treatment of castration-resistant prostate cancer (CRPC) to select and sequence therapy

  • Assess considerations in determining optimal sequences of therapy for patients with metastatic CRPC

  • Identify predictive and prognostic biomarkers to establish individualized treatment plans for patients with CRPC

  • Discuss current guidelines for patients with CRPC, based on patient- and disease-related characteristics, for optimal diagnosis and treatment strategies

  • Provide strategies to manage the challenges associated with treating CPRC, including adherence and treatment-related side effects

Faculty: E. David Crawford, MD
Professor of Surgery
E. David Crawford Distinguished
Endowed Chair in Urology
Head Urologic Oncology
University of Colorado, Denver


Dr. Crawford reported financial relationships with 3D Biopsy, Bayer, Carden Jennings Publications, Dendreon, Ferring, Johnson and Johnson, MDxHealth, Medivation/Astellas, Myriad Genetics, Opko, Precision Biopsy, Prostate Cancer Education Council, UroEd, Urotoday/Digital Science Press. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue